{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T03:30:47Z","timestamp":1792899047571,"version":"4.5.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T00:00:00Z","timestamp":1713398400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004628","name":"AstraZeneca UK Limited","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004628","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007313","name":"University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","award":["P30 CA016672"],"award-info":[{"award-number":["P30 CA016672"]}],"id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100021053","name":"Aravive, Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100021053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"NCI","doi-asserted-by":"publisher","award":["T32 CA101642"],"award-info":[{"award-number":["T32 CA101642"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA217685"],"award-info":[{"award-number":["CA217685"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["iScience"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.isci.2024.109801","type":"journal-article","created":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T03:20:26Z","timestamp":1713842426000},"page":"109801","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Phase 1b study of batiraxcept in combination with durvalumab in patients with platinum-resistant ovarian cancer"],"prefix":"10.1016","volume":"27","author":[{"given":"Anne","family":"Knisely","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily M.","family":"Hinchcliff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Gardiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reshma","family":"Rangwala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Lito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan","family":"Fellman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil K.","family":"Sood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon N.","family":"Westin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen H.","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir A.","family":"Jazaeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.isci.2024.109801_bib1","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa020177","article-title":"Intratumoral T\u00a0cells, recurrence, and survival in epithelial ovarian cancer","volume":"348","author":"Zhang","year":"2003","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.isci.2024.109801_bib2","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/annonc\/mdz135","article-title":"Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study","volume":"30","author":"Matulonis","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.isci.2024.109801_bib3","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1200\/JCO.21.00334","article-title":"Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA)","volume":"39","author":"Hamanishi","year":"2021","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.isci.2024.109801_bib4","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1001\/jamaoncol.2018.6258","article-title":"Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial","volume":"5","author":"Disis","year":"2019","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.isci.2024.109801_bib5","doi-asserted-by":"crossref","first-page":"viii1","DOI":"10.1093\/annonc\/mdx444","article-title":"Immunotherapy in ovarian cancer","volume":"28","author":"Odunsi","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.isci.2024.109801_bib6","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1073\/pnas.0909333107","article-title":"Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival","volume":"107","author":"Gjerdrum","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.isci.2024.109801_bib7","doi-asserted-by":"crossref","first-page":"4742","DOI":"10.1158\/1078-0432.CCR-08-2514","article-title":"Differential Expression of Axl and Gas6 in Renal Cell Carcinoma Reflecting Tumor Advancement and Survival","volume":"15","author":"Gustafsson","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.isci.2024.109801_bib8","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1593\/neo.05640","article-title":"Expression of Axl in Lung Adenocarcinoma and Correlation with Tumor Progression","volume":"7","author":"Shinh","year":"2005","journal-title":"Neoplasia"},{"key":"10.1016\/j.isci.2024.109801_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2020.07.010","article-title":"AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer","volume":"138","author":"Cardone","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.isci.2024.109801_bib10","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/238284","article-title":"Meta-analysis of microarray data identifies GAS6 expression as an independent predictor of poor survival in ovarian cancer","volume":"2013","author":"Buehler","year":"2013","journal-title":"BioMed Res. Int."},{"key":"10.1016\/j.isci.2024.109801_bib11","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s12943-019-1090-3","article-title":"AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications","volume":"18","author":"Zhu","year":"2019","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.isci.2024.109801_bib12","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1158\/1541-7786.MCR-21-0302","article-title":"GAS6\/AXL Inhibition Enhances Ovarian Cancer Sensitivity to Chemotherapy and PARP Inhibition through Increased DNA Damage and Enhanced Replication Stress","volume":"20","author":"Mullen","year":"2022","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.isci.2024.109801_bib13","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1111\/1759-7714.13166","article-title":"Tumor tissue and plasma levels of AXL and GAS6 before and after tyrosine kinase inhibitor treatment in EGFR-mutated non-small cell lung cancer","volume":"10","author":"Nonagase","year":"2019","journal-title":"Thorac. Cancer"},{"key":"10.1016\/j.isci.2024.109801_bib14","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1007\/s10120-020-01066-4","article-title":"Inhibiting the GAS6\/AXL axis suppresses tumor progression by blocking the interaction between cancer-associated fibroblasts and cancer cells in gastric carcinoma","volume":"23","author":"Bae","year":"2020","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.isci.2024.109801_bib15","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.cell.2007.10.034","article-title":"TAM receptors are pleiotropic inhibitors of the innate immune response","volume":"131","author":"Rothlin","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.isci.2024.109801_bib16","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/s41571-023-00813-7","article-title":"TAM family kinases as therapeutic targets at the interface of cancer and immunity","volume":"20","author":"DeRyckere","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.isci.2024.109801_bib17","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms13898","article-title":"Reprogramming the immunological microenvironment through radiation and targeting Axl","volume":"7","author":"Aguilera","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.isci.2024.109801_bib18","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1364","article-title":"SKI-G-801, an AXL kinase inhibitor, blocks metastasis through inducing anti-tumor immune responses and potentiates anti-PD-1 therapy in mouse cancer models","volume":"11","author":"Synn","year":"2022","journal-title":"Clin. Transl. Immunol."},{"key":"10.1016\/j.isci.2024.109801_bib19","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cell.2016.02.065","article-title":"Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma","volume":"165","author":"Hugo","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.isci.2024.109801_bib20","doi-asserted-by":"crossref","first-page":"5712","DOI":"10.1038\/ncomms6712","article-title":"Low MITF\/AXL ratio predicts early resistance to multiple targeted drugs in melanoma","volume":"5","author":"M\u00fcller","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.isci.2024.109801_bib21","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.ygyno.2021.08.020","article-title":"Phase 1b study of AVB-500 in combination with paclitaxel or pegylated liposomal doxorubicin platinum-resistant recurrent ovarian cancer","volume":"163","author":"Fuh","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.isci.2024.109801_bib22","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.ygyno.2014.02.038","article-title":"\u201cPlatinum resistant\u201d ovarian cancer: What is it, who to treat and how to measure benefit?","volume":"133","author":"Davis","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.isci.2024.109801_bib23","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1093\/annonc\/mdu363","article-title":"A randomised, placebo-controlled trial of weekly paclitaxel and saracatinib (AZD0530) in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer","volume":"25","author":"McNeish","year":"2014","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.isci.2024.109801_bib24","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1200\/JCO.2001.19.4.1001","volume":"19","author":"Markman","year":"2001","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.isci.2024.109801_bib25","unstructured":"Davis, C. Aravive Announces Top-Line Results from Phase 3 AXLerate-OC Study of Batiraxcept in Platinum-Resistant Ovarian Cancer. https:\/\/www.biospace.com\/article\/releases\/aravive-announces-top-line-results-from-phase-3-axlerate-oc-study-of-batiraxcept-in-platinum-resistant-ovarian-cancer\/#:\u223c:text=(Nasdaq%3A%20ARAV%2C%20%E2%80%9Cthe,its%20primary%20endpoint%20of%20progression%2D"},{"key":"10.1016\/j.isci.2024.109801_bib26","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1158\/1535-7163.MCT-18-0537","article-title":"Therapeutic Inhibition of the Receptor Tyrosine Kinase AXL Improves Sensitivity to Platinum and Taxane in Ovarian Cancer","volume":"18","author":"Quinn","year":"2019","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.isci.2024.109801_bib27","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41698-018-0063-0","article-title":"Tumor evolution and chemoresistance in ovarian cancer","volume":"2","author":"Kim","year":"2018","journal-title":"NPJ Precis. Oncol."},{"key":"10.1016\/j.isci.2024.109801_bib28","doi-asserted-by":"crossref","first-page":"9953","DOI":"10.3390\/ijms22189953","article-title":"Therapeutic Targeting of the Gas6\/Axl Signaling Pathway in Cancer","volume":"22","author":"Tanaka","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.isci.2024.109801_bib29","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.isci.2024.109801_bib30","doi-asserted-by":"crossref","first-page":"4291","DOI":"10.1158\/1078-0432.CCR-16-0592","article-title":"Bayesian Optimal Interval Design: A Simple and Well-Performing Design for Phase I Oncology Trials","volume":"22","author":"Yuan","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.isci.2024.109801_bib31","doi-asserted-by":"crossref","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","article-title":"Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria","volume":"15","author":"Wolchok","year":"2009","journal-title":"Clin. Cancer Res."}],"container-title":["iScience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S258900422401023X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S258900422401023X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T01:35:22Z","timestamp":1783474522000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S258900422401023X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S258900422401023X"],"URL":"https:\/\/doi.org\/10.1016\/j.isci.2024.109801","relation":{},"ISSN":["2589-0042"],"issn-type":[{"value":"2589-0042","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase 1b study of batiraxcept in combination with durvalumab in patients with platinum-resistant ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"iScience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.isci.2024.109801","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"109801"}}